The results of the KEYNOTE-689 trial reported by Uppaluri et al. (July 3 issue)1 are highly important. The addition of perioperative pembrolizumab has become the new standard of ...

The painkilling, antipyretic, and antiinflammatory properties of aspirin have been known for centuries. The understanding that aspirin targets cyclooxygenase-1 (COX-1) (also known as ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...

The planned implementation of Medicaid work requirements provides an opportunity to obtain longitudinal data to guide ...

Tobacco use kills more than 7 million people worldwide each year, including 1.3 million who die from the effects of exposure to secondhand smoke.1 As a major contributor to cancer, cardiovascular ...

Michael Welsh, Jesús González, and Paul Negulescu have won the 2025 Lasker–DeBakey Clinical Medical Research Award for their roles in developing treatments for cystic fibrosis.

Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung ...

There is an urgent need for low- and middle-income countries to ensure equitable, affordable, and sustained access to tobacco-cessation medications at scale.

A 54-year-old woman with infiltrating ductal carcinoma of the right breast treated with locoregional radiation presented with cough, fever, and dyspnea. CT showed fibrotic and ground-glass opacities ...

To the Editor: The BROADWAY trial by Nicholls and colleagues (July 3 issue) 1 was a pivotal evaluation of an intriguing agent. However, I am concerned about the use of placebo in patients with ...

Syphilis is one of the oldest known diseases. Approximately 209,000 cases were reported in the United States in 2023 — the highest number of reported cases since 1950 — including nearly 4000 ...

Surgery is the main treatment for early-stage non–small-cell lung cancer (NSCLC), even though recurrence remains common. 1 Neoadjuvant chemotherapy has offered a modest survival benefit, 2 with few ...